Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/13325
Full metadata record
DC FieldValueLanguage
dc.contributor.authorÇetinkaya, Melisa-
dc.contributor.authorBaran, Yusuf-
dc.date.accessioned2023-04-19T12:37:47Z-
dc.date.available2023-04-19T12:37:47Z-
dc.date.issued2023-
dc.identifier.issn2076-393X-
dc.identifier.urihttps://doi.org/10.3390/vaccines11030554-
dc.identifier.urihttps://hdl.handle.net/11147/13325-
dc.description.abstractCancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids-natural compounds produced by plants as secondary metabolites for cancer therapy-has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofVaccineen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFlavonoidsen_US
dc.subjectLuteolinen_US
dc.subjectAnticanceren_US
dc.subjectApoptosisen_US
dc.subjectCell cycle regulationen_US
dc.subjectAngiogenesisen_US
dc.subjectMetastasisen_US
dc.subjectNanodelivery systemsen_US
dc.subjectmiRNAsen_US
dc.titleTherapeutic potential of luteolin on canceren_US
dc.typeReviewen_US
dc.departmentİzmir Institute of Technology. Molecular Biology and Geneticsen_US
dc.identifier.volume11en_US
dc.identifier.issue3en_US
dc.identifier.wosWOS:000958238000001en_US
dc.identifier.scopus2-s2.0-85151557629en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.3390/vaccines11030554-
dc.identifier.pmid36992138en_US
dc.authorscopusid58169672700-
dc.authorscopusid9636164400-
dc.identifier.scopusqualityQ1-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.dept04.03. Department of Molecular Biology and Genetics-
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
vaccines-11-00554.pdf2.84 MBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

21
checked on Apr 5, 2024

WEB OF SCIENCETM
Citations

15
checked on Mar 23, 2024

Page view(s)

54
checked on Apr 29, 2024

Download(s)

26
checked on Apr 29, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.